Azione MIST MILESTONE PHARMACEUTICALS INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Milestone Pharmaceuticals Inc.

Azioni

MIST

CA59935V1076

Mercato chiuso - Nasdaq
Altri mercati azionari
 22:00:00 05/07/2024 		Variaz. 5gg Var. 1 gen.
1,33 USD +0,38% Grafico intraday di Milestone Pharmaceuticals Inc. +0,76% -20,36%
20/06 Transcript : Milestone Pharmaceuticals Inc. - Special Call
29/05 Milestone Pharmaceuticals dichiara che la FDA statunitense accetta la domanda di autorizzazione per Cardamyst spray nasale per l'aritmia MT

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024
Milestone Pharmaceuticals : Corporate Presentation
Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference
Milestone Pharmaceuticals Says US FDA Accepts New Drug Application for Cardamyst Nasal Spray for Arrhythmia
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST?
Certain Pre-Funded Warrants of Milestone Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2024.
Certain Options of Milestone Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2024.
Certain Common Shares of Milestone Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2024.
Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness
Milestone Pharmaceuticals: Q1 Earnings Snapshot
Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
Milestone Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Milestone Pharmaceuticals : Corporate Presentation
Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients? Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione MIST
  4. Notizie Milestone Pharmaceuticals Inc.
  5. Altre lingue